The claims and ensuing settlement revolve around Biohaven’s CGRP receptor antagonist Nurtec ODT, which is cleared to both treat and prevent migraines in adults. The drug, which was the crown ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients ...

The government asserted that Biohaven’s fraud stopped in October 2022, when Pfizer acquired the company and terminated the Nurtec speaker programmes. "We are pleased to put this legacy matter ...

30, 2022, Biohaven Pharmaceuticals violated the federal False Claims Act by providing speaker honoraria and meals at high-end restaurants to doctors, to induce them to prescribe Nurtec more often.

World-recognized brand Pfizer has agreed to a nearly $60 million financial agreement to settle claims that a wholly-owned subsidiary, Biohaven Pharmaceutical Holding Company Ltd. (Biohaven ...

Biohaven Pharmaceutical Holding, from March 2020 through September 2022, selected certain healthcare providers to be part of a group to promote its drug Nurtec ODT, a migraine treatment ...

NEW YORK (Reuters) - Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the ...

Pfizer ended the Nurtec speaker programs after paying $11.5 billion to buy Biohaven. "Patients deserve to know that their doctor is prescribing medications based on their doctor’s medical ...